Discover
DYN
Dyne Therapeutics, Inc.
26.45
1 x 26.47
3 x 26.50
bid
ask
-
0.05
0.17%
12:33 PM
timesize
| Ytd | 35.25% | |
| 1y | 135.36% |
26.18
day range
26.95
11.17
52 week range
27.13
| Open | 26.87 | Prev Close | 26.50 | Low | 26.18 | High | 26.95 | Mkt Cap | 4.95B |
| Vol | 360.52K | Avg Vol | 2.19M | EPS | -3.22 | P/E | -8.22 | Forward P/E | -8.04 |
| Beta | 1.07 | Short Ratio | 8.91 | Inst. Own | 103.26% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-27 | 50-d Avg | 22.05 | 200-d Avg | 19.40 | 1yr Est | 39.40 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-04 | 2026-09 | -0.86 | N/A | N/A | N/A |
| 2026-07-30 | 2026-06 | -0.75 | -1.08 | -0.33 | -44.23% |
| 2026-05-11 | 2026-03 | -0.77 | -0.73 | 0.04 | 5.48% |
| 2026-03-02 | 2025-12 | -0.74 | -0.76 | -0.02 | -2.70% |
| 2025-11-05 | 2025-09 | -0.81 | -0.76 | 0.05 | 6.17% |
| 2025-07-28 | 2025-06 | -0.99 | -0.97 | 0.02 | 2.02% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-31 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-07-30 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-07-23 | Cantor Fitzgerald | Upgrade | Overweight | |
| 2026-06-26 | TD Cowen | Upgrade | Buy | |
| 2026-05-15 | Evercore ISI Group | Upgrade | Outperform | Outperform |
| 2026-05-13 | Bernstein | Upgrade | Market Perform | Market Perform |
Profile
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-03-10 | BESKROVNAYA OXANA | Officer | 195.84K | Sale |
| 2026-06-15 | COX JOHN | Chief Executive Officer | 440.15K | Sale |
| 2024-08-18 | FARWELL WILDON | Officer | 143.22K | Sale |
| 2026-06-15 | FRIEDL-NADERER JOHANNA | Officer | 154.21K | Sale |
| 2024-09-17 | HIGH SUSANNA GATTI | Chief Operating Officer | 131.64K | Sale |
| 2026-06-15 | KERR DOUGLAS | Officer | 169.16K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | T. Rowe Price Investment Management, Inc. | 30.79M | 815.82M | 16.49% |
| 2026-03-30 | Janus Henderson Group PLC | 13.65M | 361.66M | 7.31% |
| 2026-06-29 | Blackrock Inc. | 12.40M | 328.71M | 6.64% |
| 2026-03-30 | Atlas Venture Life Science Advisors, LLC | 9.13M | 241.96M | 4.89% |
| 2026-03-30 | FMR, LLC | 8.91M | 236.09M | 4.77% |
| 2026-06-29 | State Street Corporation | 7.46M | 197.64M | 3.99% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | T. Rowe Price Small-Cap Stock Fund, Inc. | 7.01M | 185.82M | 3.75% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 4.65M | 123.11M | 2.49% |
| 2026-03-30 | T. Rowe Price Small-Cap Value Fund, Inc. | 4.63M | 122.56M | 2.48% |
| 2026-06-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 4.14M | 109.63M | 2.22% |
| 2026-03-30 | T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 3.81M | 100.96M | 2.04% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 3.57M | 94.64M | 1.91% |